Neurological Sciences

, Volume 38, Issue 3, pp 445–450 | Cite as

Association between brain structural anomalies, electroencephalogram and history of seizures in Mucopolysaccharidosis type II (Hunter syndrome)

  • Ramón Ernesto Jiménez-Arredondo
  • Aniel Jessica Leticia Brambila-Tapia
  • Francisco Miguel Mercado-Silva
  • Martha Ortiz-Aranda
  • Verónica Benites-Godinez
  • Graciela Olmos-García-de-ALBA
  • Luis Eduardo Figuera
Original Article

Abstract

Mucopolysaccharidosis type II or Hunter syndrome (MPS II) is a genetic disease that can course with intellectual impairment and central nervous system (CNS) alterations. To date, no report has documented electroencephalogram (EEG) measures associated with CNS alterations, detected by imaging studies, and the history of seizures in patients with MPS II. Therefore, we decided to search this association. We included 9 patients with MPS II and performed imaging studies of the brain to detect the presence of cortico-subcortical atrophy, enlarged subarachnoid space and supratentorial ventricular size. Additionally, we performed EEG studies in sleep and awake conditions and a complete clinical description. Five out of the nine patients presented history of seizures and all except one patient (88.9%) presented some CNS structural alteration in the imaging studies, being the most frequent the cortico-subcortical atrophy (77.8%). The EEG results showed low amplitude in all patients and low voltage in sleep condition in eight patients with interhemispheric asymmetry in six patients during awake and sleep conditions. Although the five patients with history of seizures did not present a distinctive EEG anomaly, four of them presented some structural alteration in the imaging studies. In conclusion, most patients presented structural alterations in the CNS; likewise, all of them presented EEG anomalies mainly during sleep conditions. However, a clear association between EEG, CNS and the history of seizures was not established.

Keywords

Mucopolysaccharidosis type II Hunter syndrome Electroencephalogram Magnetic resonance imaging 

References

  1. 1.
    Fan Z, Styner M, Muenzer J, Poe M, Escolar M (2010) Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II. AJNR Am J Neuroradiol 31:1319–1323CrossRefPubMedGoogle Scholar
  2. 2.
    Froissart R, Da Silva IM, Maire I (2007) Mucopolysaccharidosis type II: an update on mutation spectrum. Acta Paediatr 96:71–77CrossRefPubMedGoogle Scholar
  3. 3.
    Holt JB, Poe MD, Escolar LM (2011) Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics 127:e1258–e1265CrossRefPubMedGoogle Scholar
  4. 4.
    Lago-Albuquerque RM, Noronha-Liberalesso PB, Schmitz-Ferreira ML, Klagenberg KF, Jurkiewicz AL, Zeigelboim BS (2010) Aspectos Electrencefalográficos em Criancas com Mucopolissacaridose. J Epilepsy Clin Neurophysiol 16:162–166CrossRefGoogle Scholar
  5. 5.
    Matheus MG, Castillo M, Smith JK, Armao D, Towle D, Muenzer J (2004) Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 46:665–672CrossRefGoogle Scholar
  6. 6.
    Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP (2010) Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 19:4871–4885CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ross ME (2002) Brain malformations, epilepsy, and infantile spasms. Int Rev Neurobiol 49:333–352CrossRefPubMedGoogle Scholar
  8. 8.
    Vedolin L, Schwartz IV, Komlos M, Schuch A, Puga AC, Pinto LL et al (2007) Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. AJNR Am J Neuroradiol 28:1029–1033CrossRefPubMedGoogle Scholar
  9. 9.
    Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N et al (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2016

Authors and Affiliations

  • Ramón Ernesto Jiménez-Arredondo
    • 1
  • Aniel Jessica Leticia Brambila-Tapia
    • 2
  • Francisco Miguel Mercado-Silva
    • 3
  • Martha Ortiz-Aranda
    • 3
  • Verónica Benites-Godinez
    • 1
  • Graciela Olmos-García-de-ALBA
    • 4
  • Luis Eduardo Figuera
    • 5
    • 6
  1. 1.Hospital General No. 1Instituto Mexicano del Seguro Social (IMSS)TepicMexico
  2. 2.Departamento de Psicología BásicaUniversidad de Guadalajara (CUCS)GuadalajaraMexico
  3. 3.Centro Médico Nacional de Occidente (CMNO), Hospital de Pediatría, Instituto Mexicano del Seguro Social (IMSS)GuadalajaraMexico
  4. 4.Hospital Infantil de MéxicoMéxicoMexico
  5. 5.Centro de Investigación Biomédica de OccidenteInstituto Mexicano del Seguro Social (IMSS)GuadalajaraMexico
  6. 6.División de GenéticaCIBO-IMSSGuadalajaraMexico

Personalised recommendations